Prediabetes and Lifestyle Modification: Time to Prevent a Preventable Disease

Overview

Journal Perm J

Specialties General Medicine
Health Services

Date 2014 Aug 8

PMID 25102521

Citations 102

Authors

Phillip Tuso

Affiliations

Soon will be listed here.

Abstract

More than 100 million Americans have prediabetes or diabetes. Prediabetes is a condition in which individuals have blood glucose levels higher than normal but not high enough to be classified as diabetes. People with prediabetes have an increased risk of Type 2 diabetes. An estimated 34% of adults have prediabetes. Prediabetes is now recognized as a reversible condition that increases an individual's risk for development of diabetes. Lifestyle risk factors for prediabetes include overweight and physical inactivity.Increasing awareness and risk stratification of individuals with prediabetes may help physicians understand potential interventions that may help decrease the percentage of patients in their panels in whom diabetes develops. If untreated, 37% of the individuals with prediabetes may have diabetes in 4 years. Lifestyle intervention may decrease the percentage of prediabetic patients in whom diabetes develops to 20%.Long-term data also suggest that lifestyle intervention may decrease the risk of prediabetes progressing to diabetes for as long as 10 years. To prevent 1 case of diabetes during a 3-year period, 6.9 persons would have to participate in the lifestyle intervention program. In addition, recent data suggest that the difference in direct and indirect costs to care for a patient with prediabetes vs a patient with diabetes may be as much as $7000 per year. Investment in a diabetes prevention program now may have a substantial return on investment in the future and help prevent a preventable disease.

Citing Articles

Association of dietary decanoic acid intake with diabetes or prediabetes: an analysis from NHANES 2005-2016.

Zhu H, Fu Q, Chen R, Luo L, Yu M, Zhou Y Front Nutr. 2025; 11():1483045.

PMID: 39839274 PMC: 11747714. DOI: 10.3389/fnut.2024.1483045.

A digital health-supported and community pharmacy-based lifestyle intervention program for adults with pre-diabetes: a study protocol for a cluster randomised controlled trial.

Teoh K, Ng C, Chong C, Cheong W, Ng Y, Bell J BMJ Open. 2024; 14(10):e083921.

PMID: 39448216 PMC: 11579589. DOI: 10.1136/bmjopen-2024-083921.

Attitude, Knowledge, and Practices Regarding Prediabetes in Saudi Arabia: A Cross-Sectional Study on Family Medicine Residents.

Aljehani F Cureus. 2024; 16(9):e69300.

PMID: 39398787 PMC: 11470977. DOI: 10.7759/cureus.69300.

Characteristics and risk factors associated with developing prediabetes in Saudi Arabia.

Tourkmani A, Alharbi T, Bin Rsheed A, Alotaibi A, AlEisaa M, Youzghadli I Ann Med. 2024; 56(1):2413922.

PMID: 39392033 PMC: 11486171. DOI: 10.1080/07853890.2024.2413922.

Prediabetes in a French overseas territory: Clinical Characteristics, Risk Factors, and Implications for type 2 diabetes prevention.

Bun R, Tounkara B, Leruste S, Kichenapanaidou L, Simonson M, Kowalczyk C Prev Med Rep. 2024; 47:102893.

PMID: 39391285 PMC: 11464243. DOI: 10.1016/j.pmedr.2024.102893.

References

Vojta D, De Sa J, Prospect T, Stevens S . Effective interventions for stemming the growing crisis of diabetes and prediabetes: a national payer's perspective. Health Aff (Millwood). 2012; 31(1):20-6. DOI: 10.1377/hlthaff.2011.0327. View

Salpeter S, Buckley N, Kahn J, Salpeter E . Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008; 121(2):149-157.e2. DOI: 10.1016/j.amjmed.2007.09.016. View

Lily M, Lilly M, Godwin M . Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician. 2009; 55(4):363-9. PMC: 2669003. View

Gerstein H, Mohan V, Avezum A, Bergenstal R, Chiasson J, Garrido M . Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia. 2010; 54(3):487-95. DOI: 10.1007/s00125-010-1985-4. View

Sjostrom L, Lindroos A, Peltonen M, Torgerson J, Bouchard C, Carlsson B . Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004; 351(26):2683-93. DOI: 10.1056/NEJMoa035622. View

Sjostrom L, Peltonen M, Jacobson P, Sjostrom C, Karason K, Wedel H . Bariatric surgery and long-term cardiovascular events. JAMA. 2012; 307(1):56-65. DOI: 10.1001/jama.2011.1914. View

Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J . The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003; 26(12):3230-6. DOI: 10.2337/diacare.26.12.3230. View

Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H . HbA1c 5·7-6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet. 2011; 378(9786):147-55. DOI: 10.1016/S0140-6736(11)60472-8. View

. Summary of revisions to the 2011 clinical practice recommendations. Diabetes Care. 2011; 34 Suppl 1:S3. PMC: 3006057. DOI: 10.2337/dc11-S003. View

10.

Zhang Y, Dall T, Chen Y, Baldwin A, Yang W, Mann S . Medical cost associated with prediabetes. Popul Health Manag. 2009; 12(3):157-63. DOI: 10.1089/pop.2009.12302. View

11.

Knowler W, Barrett-Connor E, Fowler S, Hamman R, Lachin J, Walker E . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6):393-403. PMC: 1370926. DOI: 10.1056/NEJMoa012512. View

12.

Li G, Zhang P, Wang J, Gregg E, Yang W, Gong Q . The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008; 371(9626):1783-9. DOI: 10.1016/S0140-6736(08)60766-7. View

13.

Williams D, Cadwell B, Cheng Y, Cowie C, Gregg E, Geiss L . Prevalence of impaired fasting glucose and its relationship with cardiovascular disease risk factors in US adolescents, 1999-2000. Pediatrics. 2005; 116(5):1122-6. DOI: 10.1542/peds.2004-2001. View

14.

Gong Q, Gregg E, Wang J, An Y, Zhang P, Yang W . Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2010; 54(2):300-7. DOI: 10.1007/s00125-010-1948-9. View

15.

Hopper I, Billah B, Skiba M, Krum H . Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil. 2011; 18(6):813-23. DOI: 10.1177/1741826711421687. View

16.

. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011; 34 Suppl 1:S62-9. PMC: 3006051. DOI: 10.2337/dc11-S062. View

17.

Dagenais G, Gerstein H, Holman R, Budaj A, Escalante A, Hedner T . Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008; 31(5):1007-14. DOI: 10.2337/dc07-1868. View

18.

Yokoi T . Troglitazone. Handb Exp Pharmacol. 2009; (196):419-35. DOI: 10.1007/978-3-642-00663-0_14. View

19.

Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson J, Hemio K . Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006; 368(9548):1673-9. DOI: 10.1016/S0140-6736(06)69701-8. View

20.

Barr E, Zimmet P, Welborn T, Jolley D, Magliano D, Dunstan D . Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007; 116(2):151-7. DOI: 10.1161/CIRCULATIONAHA.106.685628. View